Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to announce earnings of ($1.78) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Esperion Therapeutics’ earnings, with estimates ranging from ($1.95) to ($1.61). Esperion Therapeutics posted earnings per share of ($0.77) during the same quarter last year, which would indicate a negative year-over-year growth rate of 131.2%. The business is expected to report its next earnings results on Thursday, November 2nd.

On average, analysts expect that Esperion Therapeutics will report full year earnings of ($7.17) per share for the current fiscal year, with EPS estimates ranging from ($7.66) to ($6.54). For the next financial year, analysts forecast that the firm will report earnings of ($6.00) per share, with EPS estimates ranging from ($9.36) to ($4.42). Zacks’ EPS averages are an average based on a survey of research analysts that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same period in the prior year, the firm earned ($0.62) EPS.

A number of research analysts have recently commented on the company. Cowen and Company assumed coverage on Esperion Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $64.00 target price for the company. Northland Securities started coverage on Esperion Therapeutics in a report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 price target on the stock. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Jefferies Group LLC restated a “buy” rating and set a $85.00 price target on shares of Esperion Therapeutics in a report on Monday, August 21st. Finally, Bank of America Corporation restated a “neutral” rating and set a $60.00 price target on shares of Esperion Therapeutics in a report on Friday, August 11th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Esperion Therapeutics has an average rating of “Buy” and a consensus target price of $52.54.

A number of hedge funds have recently added to or reduced their stakes in ESPR. Teachers Advisors LLC increased its stake in Esperion Therapeutics by 56.7% in the fourth quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock worth $419,000 after purchasing an additional 12,122 shares during the period. Bank of Montreal Can increased its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 6,000 shares during the period. Nationwide Fund Advisors increased its stake in Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock worth $1,387,000 after purchasing an additional 921 shares during the period. Russell Investments Group Ltd. purchased a new stake in Esperion Therapeutics in the first quarter worth $961,000. Finally, Wells Fargo & Company MN increased its stake in Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 3,282 shares during the period. Institutional investors and hedge funds own 83.33% of the company’s stock.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 1.52% on Thursday, hitting $50.65. 316,306 shares of the company traded hands. The stock’s market capitalization is $1.14 billion. The firm’s 50 day moving average price is $47.87 and its 200-day moving average price is $40.07. Esperion Therapeutics has a 1-year low of $9.40 and a 1-year high of $57.38.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/brokerages-expect-esperion-therapeutics-inc-espr-to-post-1-78-earnings-per-share.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.